Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

GRI Bio, Inc.

Contributing Author

Recent Articles by GRI Bio, Inc.

Sep-11	GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
Sep-03	GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference GRI GlobeNewswire
Aug-14	GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech GRI GlobeNewswire
Jul-31	GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment GRI GlobeNewswire
Jul-31	GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
Jul-22	GRI Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference GRI GlobeNewswire
Jul-01	GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
Jun-26	GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
May-22	GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results GRI GlobeNewswire
May-21	GRI Bio to Participate in the Virtual Investor Closing Bell Series GRI GlobeNewswire
May-16	GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase GRI GlobeNewswire
May-15	GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 GRI GlobeNewswire
May-08	GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
May-07	GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.